COVID-19 : effects in comorbidities and special populations / Sanjay Kumar Bhadada [and three others].

Format:

Book

Author/Creator:

Bhadada, Sanjay Kumar, author.

Language:

English

Subjects (All):

COVID-19 (Disease).

Comorbidity.

Older people--Health and hygiene.

Older people.

Physical Description:

1 online resource (390 pages)

Edition:

First edition.

Place of Publication:

Singapore : Bentham Science Publishers, [2022]

Summary:

Coronavirus disease 2019 (COVID-19) has affected millions of people across the world. Clinicians and scientists across the globe need all the information of this pandemic on one platform. Today, it is also necessary to find out the association of COVID-19 with various medical comorbidities, and its effect on vulnerable populations that require special medical attention. This information will be helpful for the management of COVID-19. COVID-19: Effects in Comorbidities and Special Populations is a concise and visual reference for information about this viral disease and its relationship with different medical conditions. The book provides comprehensive knowledge covering COVID-19 comorbidities (for example, CVD, Diabetes, lung diseases, etc.), and the incidence in specific groups (for example, children and the elderly). Chapters outline the features and the management of the disease in specific conditions. Key Features: ✓ 12 chapters covering several aspects of COVID-19 management, making this a perfect text book for virologist and medical students ✓ Focused and structured description of different effects of COVID-19 in specific patient groups ✓ Multiple tables and figures which summarizes and highlight important points ✓ Multiple choice questions for learners ✓ Detailed list of references, abbreviations and symbols This book is an essential reference for practicing and training virologists, pulmonologists, medical students and scientists working in research labs, pharmaceutical and biotechnology industries in connection with the control of COVID-19 infectio.

Contents:

Cover

Title

Copyright

End User License Agreement

Contents

Preface

KEY FEATURES:

List of Contributors

SARS-CoV-2 and Co-morbidities

Yara S. Beyh1, Riya Sachdeva2, K. M.Venkat Narayan1 and Manoj Bhasin2,3,*

HIGHLIGHTS

INTRODUCTION

COVID-19: GENERAL CHARACTERISTICS, SUSCEPTIBILITY, AND ASSOCIATION WITH THE IMMUNE SYSTEM

COVID-19 AND CO-MORBIDITIES

Diabetes Mellitus

Obesity and Metabolic Syndrome

Chronic Kidney Disease

Cardiovascular Diseases

Cancer

Sickle Cell

Chronic Obstructive Pulmonary Disease

CONCLUSION

MULTIPLE CHOICE QUESTIONS

LIST OF ABBREVIATIONS

CONSENT FOR PUBLICATION

CONFLICT OF INTEREST

ACKNOWLEDGEMENTS

REFERENCES

Diabetes Mellitus and COVID-19

Sanjay Kumar Bhadada1,* and Rimesh Pal1

EPIDEMIOLOGY

PATHOPHYSIOLOGICAL ASSOCIATIONS BETWEEN DIABETES MELLITUS AND COVID-19

Advancing Age

Comorbidities

Obesity

Dysregulated Immune System

Angiotensin-Converting Enzyme 2 (ACE2) And Diabetes Mellitus

Coagulation

TWO-WAY INTERACTIONS BETWEEN DIABETES MELLITUS AND COVID-19

DOES GLYCEMIC CONTROL BEFORE, AT, AND AFTER ADMISSION PREDICT OUTCOMES IN COVID-19 PATIENTS WITH DIABETES MELLITUS?

Glycemic Control Before Hospital Admission

Plasma Glucose At Hospital Admission

In-Hospital Glycemic Control

ANTI-DIABETIC MEDICATIONS IN COVID-19

COVID-19 and Diabetic Foot

Ashu Rastogi1,*

FOOT EXAMINATION AND COVID-19

Foot Inspection

Neurological Assessment

Vascular Assessment

DIABETIC FOOT INFECTIONS AND COVID-19 PANDEMIC

An Easy Guide to Antibiotic Therapy is as Follows

DFI, COVID-19 AND WAY FORWARD.

CHARCOT FOOT AND COVID-19

PREVENTIVE FOOT CARE DURING COVID-19 PANDEMIC

FOOT CARE IN PATIENTS WITH PRE-EXISTING WOUNDS DURING COVID-19 PANDEMIC

DRESSING OF FOOT WOUND DURING COVID -19 PANDEMIC

FOOT CARE FOR DFI DURING COVID-19

WHO SHOULD BE HOSPITALIZED FOR FOOT COMPLICATIONS?

UTILIZATION OF TELE-HEALTH SERVICES FOR DIABETIC FOOT DURING COVID-19

PROMOTE SELF CARE (FOOT) DURING COVID-19

PRECAUTIONS FOR HEALTH CARE PROVIDERS

Gastrointestinal and Hepatobiliary Manifestations of COVID-19

Rohit Mehtani1 and Sunil Taneja1,*

GI TROPISM OF SARS-COV-2

GI SYMPTOMATOLOGY

Relation of GI Symptoms with COVID-19 Severity

POSSIBILITY OF FECO-ORAL TRANSMISSION OF COVID 19?

GI HISTOPATHOLOGY OF PATIENTS WITH COVID-19

MANAGEMENT OF GI SYMPTOMS IN COVID-19

LIVER INJURY WITH COVID-19

MECHANISMS OF LIVER INJURY

Role of ACE 2 and Serine protease

Direct Cytopathic Effects

Cytokine Storm

Ischaemic Hepatitis And Drug Toxicity

HISTOPATHOLOGICAL FINDINGS IN THE LIVER

COVID-19 IN PATIENTS WITH CHRONIC LIVER DISEASE

LIVER FAILURE DUE TO COVID-19

LIVER TRANSPLANTATION AND COVID-19

GI ENDOSCOPY PRACTICES DURING COVID-19 PANDEMIC

COVID-19 and Cardiovascular Manifestations

Ganesh Kasinadhuni1, Vineela Chikkam2, Parminder Singh1 and Rajesh Vijayvergiya1,*

Biology of SARS-CoV-2

Pathophysiology of SARS-Cov-2 Related Tissue Injury

ACE2 -A link to Cardiovascular (CV) Injury

COVID-19 and Cardiovascular Disease (CVD).

COVID-19 and Cardiovascular (CV) Effects

ACUTE CARDIOVASCULAR (CV) MANIFESTATIONS

Acute Cardiac Injury and Myocarditis

Management

Cardiac Arrhythmias

Acute Coronary Syndromes (ACS)

Venous Thromboembolism (VTE)

Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors And Cardiovascular Outcomes In COVID-19 Illness

Antiviral Drugs and their Cardiovascular Effects

Hydroxychloroquine (HCQ) and Azithromycin

Lopinavir-ritonavir

Long-term Cardiovascular Effects - Long COVID

COVID-19 and Hematological Manifestations

Niranjan Shiwaji Khaire1, Nishant Jindal1 and Pankaj Malhotra1,*

COVID-19 AND HEMATOLOGICAL MANIFESTATIONS

Total Leukocyte Count and Differential Count

a. Lymphopenia

b. Neutrophilic Leukocytosis

c. Thrombocytosis and Thrombocytopenia

d. Composite Variables: NLR and PLR Ratios

e. What is the Clinical Utility of Following these Alterations in the CBC?

Coagulation System

COVID-19 Coagulopathy

THROMBOSIS AND THROMBOEMBOLISM

The Large vessel Thrombosis (Venous thromboembolism and Pulmonary Thromboembolism)

Large Vessel Thrombosis (Arterial, extracorporeal circuit thrombosis)

Microvascular Thrombosis and Autopsy data on thrombosis

Pathophysiology of VTE and Immunothrombosis in COVID-19

Acute Illness

Patient-related

SARS-CoV2 Related

COVID-19 VS. NON-COVID-19 ILLNESS

TREATMENT IMPLICATIONS

COVID-19 And Chronic Kidney Diseases

Vikas Makkar1,*, Sudhir Mehta1, Suman Sethi1, Simran Kaur1 and P.M. Sohal1.

INTRODUCTION: AKI/ACUTE ON CKD IN COVID-19

Prevalence of AKI in COVID-19

Pathophysiology of Acute Kidney Injury in COVID-19

Mechanisms

Systemic Effects

Fluid Imbalance

Congestion of Renal Vein

Rhabdomyolysis

Superimposed Infections

Pathogenesis of AKI in CRS

Pro-inflammatory Cytokines

Activation-induced Cell Death

Activation of Procoagulation Pathways

Complement System Activation

Heme-Mediated Pathology

Systemic Endothelial Injury

Organ Crosstalk

Lung-Kidney Axis and Crosstalk

Mechanism of Lung-Kidney Crosstalk

Renal Medullary Hypoxia

ROLE OF ACE2 IN THE PATHOGENESIS OF RENAL INJURY

Site of ACE2 in Lungs/Kidneys

Entry of Virus into the Cell

Priming and Role of TMPRSS2

Angiotensin II

DIRECT CYTOPATHIC EFFECT

Clinical Presentation

Incidence of AKI

Timing &amp

Severity of AKI

Predictors of AKI

Kidney Abnormalities

Outcome

Renal Histopathology

COVAN

MANAGEMENT OF AKI

RECOGNITION, MONITORING, AND DIAGNOSIS OF AKI IN COVID-19 PATIENTS

Renal Replacement Therapy

Preferred Treatment Modality for AKI in COVID-19 Pandemic

Other Extracorporeal Therapies

CKD IN COVID-19

Management of Glomerular Diseases During COVID-19 Pandemic

IMMUNOSUPPRESSIVE TREATMENT IN VARIOUS KIDNEY DISEASES DURING COVID-19 PANDEMIC

Antiviral Therapy for Covid-19

Remdesivir

Hydroxychloroquine

Lopinavir-Ritonavir and Darunavir-Cobicistat

High-Dose Steroids

Tocilizumab and other Anti-Interleukin (IL)-6/IL-6R Monoclonal Antibodies (e.g., Sarilumab)

Intravenous Immunoglobulins

Ivermectin

USE OF ARBS DURING PANDEMIC

Paradoxical Effect of ACE2 Modulation in COVID-19 Outcome

COVID- 19 AND DIALYSIS

COVID 19 AND HEMODIALYSIS

Dialysis Patients and Dialysis Facilities.

Disinfection and Disposal Practices in the Dialysis Unit

Bleach Solution

Alcohol-Based Solutions

CRRT

CRRT Dosing

Modifications to CRRT for COVID- 19 Positive

OTHER EXTRACORPOREAL THERAPY FOR COVID-19

ECOS Modifications in Relation to COVID-19

Extracorporeal Therapies in CRS

The Rationale of Using CytoSorb Therapy in Critically ill COVID-19 Patients

CytoSorb Therapy - Experience in Rx of COVID-19

Recommendations for Anti-Cytokine Storm Therapy

Recommendations from Italy

Recommendations from Panama

Practical Recommendations During COVID Pandemic

PERITONEAL DIALYSIS

Role of Acute PD in the Management of CoV-AKI

Advantages

Patients Already on CAPD

New Patient Planned for CAPD

Coronavirus Disease 2019-Specific Concerns for PD

COVID 19 AND KIDNEY TRANSPLANTATION

Transplant Activity Report during this Pandemic

Data Published from India

Transmission of COVID-19 Infection During Transplantation

Selection Criteria for Donor/Recipient During COVID-19 Pandemic

Deceased Donors

Clinical Criteria (Prasad et al., 2020a).

Epidemiological Criteria

Living Related Transplants

Transplantation Recipients

Post-Transplant Follows up Measures

Precautions for Personnel Working in the Program

Clinical Presentation, Disease Course, or outcomes in the Transplant Recipient

Evidence and Experiences from Data Published

Management of Immunosuppression During COVID-19 Pandemic

COVID-19 and Pulmonary Diseases

Kuruswamy Thurai Prasad1,*

PATHOPHYSIOLOGY

TRANSMISSION AND RISK FACTORS

PULMONARY INVOLVEMENT IN COVID-19

Clinical Features

Laboratory Abnormalities.

Radiology.

Notes:

Description based on publisher supplied metadata and other sources.

Description based on print version record.

Includes bibliographical references.

ISBN:

9789815036367

981503636X

OCLC:

1344539396